Related Experiment Video
Updated: Aug 22, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Management of chronic hepatitis B
1Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9B-06, 10 Center Drive, MSC 1800, Bethesda, MD 29892-1800, USA. marcg@bldg10.niddk.nih.gov
Insights
Chronic hepatitis B (CHB) is a global health concern with distinct clinical forms. Understanding these presentations and viral-host dynamics is key to developing tailored therapies for CHB patients.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B (CHB) represents a significant global health burden, contributing to chronic liver disease.
- CHB manifests in three primary clinical forms: hepatitis B e antigen (HBeAg)-positive, HBeAg-negative, and inactive CHB.
- The progression of CHB is influenced by viral-host immunological interactions, impacting disease development.
Purpose of the Study:
- To outline the distinct clinical presentations of Chronic Hepatitis B.
- To discuss the viral-host immunological dynamics underlying CHB.
- To review current therapeutic strategies and future directions for CHB management.
Main Methods:
- Review of existing literature on CHB.
- Analysis of clinical presentations and natural history.
- Evaluation of current and emerging therapeutic options.
Main Results:
- Identification of three main clinical presentations of CHB: HBeAg-positive, HBeAg-negative, and inactive.
- Understanding the role of viral-host immunology in CHB progression.
- Availability of three licensed drugs, enabling tailored therapeutic approaches.
Conclusions:
- CHB management requires understanding its varied clinical presentations and underlying immunology.
- Tailored therapy is becoming increasingly important for effective CHB treatment.
- Future advancements promise new agents and therapeutic strategies for CHB.
Abstract:
Chronic hepatitis B (CHB) is a major worldwide cause of chronic liver disease and a significant public health issue. Three predominant clinical presentations are recognized: hepatitis B e antigen(HBeAg) or typical CHB, HBeAg-negative or atypical CHB, and inactive CHB. The natural history of CHB infection in an individual may be dominated by one or a combination of these clinical presentations in a sequential fashion. These variations in clinical presentations reflect the viral-host immunology dynamics that form the basis for the development of liver disease. Therapy has been problematic in the past. There are three licensed drugs available for therapy of CHB with varied mechanisms of action. This has introduced the concept of tailored therapy for the individual patient. Many promising new agents and therapeutic approaches should become available in the near future.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Chronic Pancreatitis II: Collaborative Care
Assessment:
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Acute Pancreatitis II: Clinical Manifestations and Management
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
